At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 908 enrolled
Drug / intervention
Eravacycline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
In Brief
A Phase 3 clinical trial evaluating Eravacycline and Levofloxacin for cUTI. Completed, enrolled 908 participants across 99 sites in 18 countries.
Detailed Summary
This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy and safety of eravacycline compared with levofloxacin in participants with complicated urinary tract infections (cUTI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionscUTI
CountriesBulgaria, Colombia, Czechia, Estonia, Georgia, Greece, Hungary, Israel, Italy, Latvia, Mexico, Moldova, Poland, Romania, Russia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartOct 2014
Primary CompletionJun 2015
Study CompletionAug 2015
TodayJul 2026
First PostedNov 8, 2013
Enrollment StartOct 6, 2014
Primary CompletionJun 3, 2015
Study CompletionAug 21, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.7 years ago
Interventions
Eravacyclinedrug
Levofloxacindrug